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Chapter I - Introduction
      Plants have been co-evolved with pathogens and pests from the time where plants first
appeared on earth. Under this pressure ofevolution, plants have developed numerous defenses
to counter attacks from pathogens and pests. One of such employed mechanisms is the
development of a vast array of metabolites that confers them selective survival advantages
against this natural pressure i'2. It is for the reason that plants holds an abundance of unique
and diverse metabolites found nowhere else. Having this knowledge, human has been taking
advantage of plant ability to solve our problems with pathogens. As a consequence, plants
have been herald as a mainstay agent for medicinal purpose from ancient to modern times 3.
Usage ofplants as a healing agent can be traced back to period of ancient humans. Clay tablet
from Mesopotamia period were the first ever record on usage ofplants to treat human disease,
where licorice (Glycyrrhiza glabra), myrrh (Commiphora species), and poppy (Papaver
somniferum) were documented and are still in use presently. Compounds isolated from
Papaver somniferum that were still in use presently include morphine, codeine, narcotine, and
papaverine (Figure I-l) 4.
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      The invaluable terrestrial plants as a source of drug candidates initiate us to delve
deeper in the research plant natural products. Countless species from the Meliaceae family
have generated much interest due to their various significant biological activities. Activities
such as insecticidal, insect anti-feedant, anti-bacterial, anti-fungal, anti-malarial, anti-cancer,
1
and anti-viral have so far been reported 4-9. Possibly the most recognizable species from
Meliaceae is Azadirachta indica (A. indica) or commonly known as neem. Traditionally use
in Ayurvedic treatment in India and its neighboring country for various ailments, neem has
been considered as one of the alternative treatment in modern time. Virtually, all part of this
part from leaf to root can be use medicinally, leading to the isolation ofover 135 compounds
iO'ii
. Some ofthe famous limonoids include nimbin and azadirachtin (Figure I-2) i2.
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      This study focused on another plant from Meliaceae family, Chisocheton ceramicus
Miq (C. ceramicus). A large canopy tree reaching 30 meter in height and bearing 40
centimeter in diameter when fully grown and were distributed in the tropic region
encompassing Malaysia, Indonesia, Brunei, Papua New Guinea, Philippines and Vietnam i3.
C. ceramicus have not been known to be used for any medicinal purposes but is largely
known as a source ofhardwood timber in its native region.
      Several researches have been done on C. ceramicus, as a result two series ofbioactive
limonoids have so far been isolated, ceramicines series and chisomicines series, respectively
(Figure I-3). Studies have showed that ceramicine B isolated from C. ceramicus possess
potent anti-malarial activity in Plasmodium falci arum strain 3D7. Additionally, ceramicine
A showed moderate cytotoxic activity on murine leukemia cell line (P388), while chisomicine
A showed weak inducible nitric oxide synthase (iNOS) inhibitory activity on LPS-stimulated
murine macrophage cell line (J774.1) i4-i7.
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Figure I-3. Known compounds from Chisocheton ceramicus
     The biological activities shown by plant natural products made it an interesting source
for various medical conditions including obesity. Obesity is a medical condition, in which a
person overall health is affected by excessive body weight due to unhealthy diet and lifestyle.
Cardiovascular disease, diabetes mellitus type 2, obstructive sleep apnea, osteoarthritis,
asthma, hypertension, and certain type of cancer are among some of the disease associated
with obesity, which are the leading preventable cause of death, particularly in developed and
developing country i8. The risks of obesity can be reduced through healthy diet and lifestyle,
and more recently by consumption of anti-obesity drugs i9. The cause ofobesity morbidity is
divided into two attributes, increase of lipid mass and increase of lipid cells numbers i8. Both
of these attributes could be decreased by reducing lipid-droplets accumulation (LDA) and
adipocyte differentiation. Apart from reducing LDA, obesity morbidity could be treated by
preventing absorption of fats from diet. This is practiced by drug called Orlistat, a lipstatin
derivative first isolated from Streptomyces toxytricini (Figure I-4) 20'2i. orlistat also
3
moderately reduces blood pressure and have been suggested to prevent onset of type 2
diabetes, which both conditions are related with obesity 22. A more controversial method, an
anorexic inducing drug, promoting weight loss through induction of satiety. This method js
utilized by a drug named Lorcaserin (Figure I-4). A 5-HT2c receptor agonist, Lorcaserin
stimulates the activation of proopiomelanocortin production and consequently suppressing
appetite 23.
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      Apart from the approved anti-obesity drugs, Orlistat and Lorcaserin, several other
botanical examples that are currently being studied for development as weight loss product
include Alpinia officinarum from Zingiberaceae family. As a result, a potent inhibitor of
pancreatic lipase, 3-methylethergalangin (Figure I-5) was identified. Ethanol extract from
Alpinia officinarum administered to Sprague-Dawley rats for a 6-week period showed
promising anti-obesity effect 24'25. Dioscorea nipponica or wild yam yielded a steroidal
saponin, pseudoprotodioscin (Figure I-5) that inhibit adipogenesis both in vitro and in vivo.
Regulation was found to be via inhibition of p38 mitogen-activated protein kinase. While
several key adipogenic genes were also repressed, including CCAATIenhancer-binding-
protein-or (CIEBPor), lipoprotein lipase (LPL), peroxisome proliferator-activated receptor
protein-y (PPARy) and leptin 26. Another example is the bitter melon or scientifically known
as Momordica charantia. Rats feed with freeze-dried juice of this plant unripe fruits shown
observable reduction in visceral fat mass and hepatic triacylglycerol 27'28. From the fruits of
Momordica charantia, momordicoside S was isolated and exhibited potent activation of 5'
adenosine monophosphate-activated protein kinase (AMPK) pathway and reduction in
adipocyte transcription factor PPARy and sterol regulatory element-binding protein-lc
(SREBPIc) 29. Berberine which was used as a positive control in this study can be isolated
from the berberis genus plants 30 (Figure I-5). It has been suggested that, berberine induced
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Figure I-5. Anti-obesity compounds from natural sources
      Research for anti-obesity drugs is ongoing but only a few make it pass clinical trials.
This currently generates a void in the discovery phase for new anti-obesity drug candidates.
To offset this matter, efforts on the discovery of new possible lead have to be intensified. On
an interesting note, only a few researches were done on limonoids with anti-obesity propenies.
A limonoid isolated from grape fruits juice, nomilin have been suggested to activate G
protein-coupled bile acid receptor 1 (TGR5) to prevent obesity 32'33. While, meliacinolin
isolated from A. indica were shown to possess in vivo anti•-diabetic property in streptozotocin-
nicotinamide-induced type 2 diabetic mice 34.
      Through our continuous screening effort to identify compounds as an anti-obesity
drug Iead, we have identified that previously isolated limonoid, ceramicines A and B from C.
ceramicus bark extract i4'i5 to possess potent anti-LDA activity. Thus further studies were
carried out on constituents of C. ceramicus bark extract. As a result, eight new limonoids,
                                     5
ceramicines E-L were isolated. Their relative structures were elucidated using ID and 2D
NMR data. These eight new limonoids potential as anti-obesity drug lead, were measure via
their ability to inhibit LDA activity on mouse pre-adipocyte cell line, MC3T3-G21PA6. Data
showed that, ceramicine I possess moderate anti-LDA activity while others showed weak or
inactive. While previously isolated ceramicine B was found to be most potent compound with
anti-LDA activity and its mechanism of action is reported in this study.
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Chapter II - Constituents of Chisocheton ceramicus
ILI Separation and Purification
      The dried ground bark of C. ceramicus (500 g) was extracted with methanol, yielding
56 g of extract. A small portion ofthe extract (7 g) was further partitioned with hexane, ethyl
acetate, n-butanol, and water, successively for small scale constituents' studies. The hexane-
soluble materials were further partitioned with a silica gel column (hexane/EtOAc, 10:O -
1:1, and then CHC131MeOH, 10:O - O:10). Fraction eluted from the silica gel column with
CHC13/MeOH (7:2) was identified as previously isolated ceramicine B i5. While, fraction
eluted from the silica gel column with CHC13!MeOH (7:3) was further purified using Cis
HPLC under gradient elution (500/o-1000/o MeOH) to yield ceramicine E (1, 2.0 mg, O.0290/o
yield), and ceramicine F (2, 9.5 mg, O.140/o yield), both as colorless solid. Fraction eluted with
CHC131MeOH (1:1) was purified also on Cis HPLC under gradient elution (700/o-1000/o
MeOH) to obtain ceramicine G (3, 5.6 mg, O.080/o yield) as colorless solid. Whereas, fraction
eluted with CHC131MeOH (4:6) was purified on Cis HPLC under gradient elution (500/o-1000/o
MeOH) to afford previously identified ceramicine C i5, and two new limonoids, ceramicine H
(4, O.3 mg, O.O040/o yield) and ceramicine I (5, 4.3 mg, O.060/o yield).
      Further isolation on minor compounds was performed on the remaining 46 g of extract.
Similarly the extract was further partitioned with hexane, ethyl acetate, n-butanol, and water,
successively. The hexane-soluble materials were panitioned with a silica gel column
(hexanelEtOAc, 10:O - 1:1, and then CHC131MeOH, 10:O - O:10). Fraction eluted from the
silica gel column with hexanelEtOAc (3:7) was idenfied as ceramicine B i5. Fraction eluted
from the silica gel column with hexanelEtOAc (1:9) was purified a silica gel column
(toluenelEtOAc, 6:1 . 4:1). Fraction eluted from the silica gel column with toluene!EtOAc
(4:1) and 1000/o EtOAc were finally purified using HPLC chiral column under isocratic
elution (78e/o1220/o MeOHIH20) to yield ceramicine J (6, 1.0 mg, O.OO020/o), ceramicine K (7,
O.6 mg, O.OOO120/o yield) and ceramicine L (8, O.8 mg, O.OOO160/o yield) together with
previously identified ceramicines A and C i4'i5, all as colorless amorphous solid.
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II.2 Structure Elucidation
II.2.1 CeramicineE(1)
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      Ceramicine E {1, [ct]D28 +20 (c O.5, CHC13)} was isolated as a colorless amorphous
solid and had molecular formula, C27H3207 as determined by high resolution-electrospray
ionization-time of flight-mass spectra (HR-ESI-TOF-MS) [mlz 469.2206 (M + H)', A -2.0
mmu]. IR absorptions suggested the presence ofa carbonyl (1718 cm-i) and a hydroxyl (3437
cm'i ) groups. iH and i3C NMR data (Tables II-1) revealed 27 carbon resonances due to two
carbonyls, two sp2 quaternary carbons, four sp3 quaternary carbons, four sp2 methines, seven
sp3 methines, four sp3 methylenes, and four methyls. Among them, two sp2 methines (6c
139.7 and 142.6), four sp3 methines (6c 52.9, 57.5, 65.3, and 74.2), one sp3 quaternary carbon
(6c 57.1), and one sp3 methylene (6c 47.7) are connected to an oxygen atom.
      Five partial structures a (from C-2 to C-3), b (from C-5 to C--7), c (from C-9 to C-12),
d (from C-15 to C-17), and e (from C-22 to C-23) were deduced from iH-iH correlation
spectroscopy (COSY) analysis of 1 in CDC13 (Figure II-3). The existence of two epoxides at
C-2 and C-3, and C-4 and C-29 was deduced by the iH and i3C chemical shifts (H-2: 6H 3.35,
C-2: 6c 52.9; H-3: 6H 3.01, C-3: 6c 57.5; C-4: 6c 57.1; H-29: 6H 2.84 and 3,24, C-29: 6c 47.7),
which was confirmed by heteronuclear multiple bond connectivity (HMBC) analysis for H-3
ofC-4, for H-5 ofC-4 and C-29, and for H2-29 to C-3 as shown in (Figure II-3). The HMBC
correlations for H-2 and H3-19 of C-1 (6c 202.3), for H3-19 of C-5 (6c 31.8), C-9 (6c 32.0),
and C-1O (6c 51.6), and for H3-30 of C-7 (6c 74.2), C-8 (6c 43.9), and C-9 bridged the partial
structures of a, b, and c through C-1, C-8, and C-1O. The HMBC correlations for H3-18 of C-
12 (6c 33.2), C-13 (6c 46.9), C-14 (6c 159.1), and C-17 (6c 51.9), for H-15 of C-13, and for
H3-30 of C-14 indicated the connectivity between structures b, c, and d. The connectivity of
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partial structure e (P-furyl ring) to d was shown by HMBC correlations for H-21 of C-17, C-
20 (6c 124.4), and C-23 (6c 142.6), and for H-22 to C-20. Further analysis of HMBC
correlations for H-6 and H-2' to C-1' (6c 170.6) indicated the presence of an acetate at C-6.
Therefore, 1 was established as a new limonoid with a cyclopenta[ct]phenanthren ring system
with a B-furyl ring at C-17, an acetate at C-6, and two epoxide rings.
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Figure II-3. Selected 2D-NMR correlations for ceramicine E (1)
     The relative stereochemistry of 1 was elucidated by nuclear overhauser effect
spectroscopy (NOESY) correlations as shown in computer-generated 3D rendering (Figure II-
3). NOESY correlations of H3-19/H-2, H-3, H-29a, and H-6, and H-61H-29b and H3-30
suggested stereochemistry oftwo epoxides, H-6, H3-19, and H3-30 to take as shown in Fig. 2.
The 3.Jproton coupling constants (3.JH=s!H-6 = 1 1.7 Hz and 3.JH-6!H-7 = 2.6 Hz) as well as NOESY
correlations ofH-9/H-5 and H3-18, H-7/H-15, and H-12alH-17 and H3-30 indicated that H-6,
H-7, and H-17 adopted a B-configurations, and H-5, H-9, and C-18 adopted an ct-
configurations as shown in Figure II-3.
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Table II-1 . iH and i3C-NMR data of 1 in CDC13 at 300 K
[6H (J, Hz)] [6c]
1
2
3
4
5
6
7
8
9
10
1la
1lb
12a
12b
13
14
15
16a
16b
17
18
19
20
21
22
23
29a
29b
30
v
2'
3.35 (d, 3.6)
3.01 (d, 3.6)
3.18 (d, 11.7)
5.32 (dd, 11.7, 2.6)
3.78 (brd, 2.6)
2.68m
1.60 m
2.35 m
1.60 m
1.91 m
5.52 (dd, 1.4, 3A)
2.40 (ddd, 15.5, 7.5, 3.4)
2.51 (ddd, 15.5, 10.9, 1.4)
2.85 (dd, 7.5, 10.9)
O.88 s
1.24 s
7.25 m
6.29 (dd, 1.6, O.6)
7.38 (dd, 1.6, 1.6)
2.84 (dd, 3.7, O.8)
3.24 (d, 3.7)
1.18 s
2.13 s
202.3
52.9
57.5
57.1
31.8
65.3
74.2
43.9
32.0
51.6
18.2
33.2
46.9
159.1
120.5
34.3
51.9
21.6
14.3
124.4
139.7
111.0
142.6
47.7
25.6
170.6
21.4
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II.2.2 Ceramicine F & G (2 & 3)
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    Ceramicine F {2, [a]D28 +101 (c O.5, CHC13)} was isolated as a colorless amorphous
solid and had molecular formula of C26H320s as determined by HR-ESI-TOF-MS [m/z
447.2120 (M + Na)', A -2.7 mmu]. IR absorptions showed the presence of carbonyl (1724
and 1679 cm-i) and hydroxyl groups (3437 cm'i). iH and i3C NMR data (Tables II-2)
revealed 26 carbon resonance due to two carbonyls, two sp2 quaternary carbons, four sp3
quaternary carbons, six sp2 methines, five sp3 methines, three sp3 methylenes and four
methyls. In which, two sp2 methines (6c 139.6 and 142.6), and two sp3 methines (6c 66.3, and
74.6) are attached to an oxygen atom. The existence of an aldehyde group attached to the C-4
(6c 51.8) was indicated by HMBC correlations for H3-29 ofC-3 (6c 143.9), C-4, C-5 (6c 44.1),
and C-28 (6c 200.9). Based on the HR-ESI-TOF-MS and 2D NMR data, the structure of2
was assigned as in Figure II-4.
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Figure II-4. Selected 2D-NMR correlations for ceramicine F (2)
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    The relative stereochemistry of 2 was elucidated by NOESY correlations as shown in
computer-generated 3D drawing (Figure II-4). As shown by Figure 3, the relative
stereochemistry was shown to be similar to 1. NOESY correlations of H-6!H3-29, H3-19, and
H3-30, and H-5/H-28, suggested the presence of the hydroxyl attached to C-6 and the
aldehyde attached to C-4 to adopt the or-configuration.
C.
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   Ceramicine G (3)
    Ceramicine G {3, [ct]D28 -39 (c O.5, CHC13)} was isolated as a white powder and had
molecular formula of C27H3406 as determined by HR-ESI-TOF-MS [m/z 447.2244 (M + Na)'.
A -O.9 mmu], which was a CH20 unit larger than ceramicine F (2). iH and i3C NMR data
(Table II-2) of3 were analogous to those of2, but instead ofan aldehyde at C-4, the presence
of a methoxycarbonyl group at C-4 (5c 47.9) was indicated by the HMBC correlations for H3-
1', H3-29, H-3, and H-5 of C-28 (6c 175.9) and H3-29 of C-3 (6c 146.4), C-4, and C-5 (6c
43.3). The NOESY correlations between H-6!H3-29, H3-19, and H3-30 suggested that
methoxycarbonyl group to adopt the or-configuration (Figure II-5).
H,Ci91, 31
        OH
   b OH
=i
 Figure II-5. Selected 2D-NMR correlations for ceramicine G (3)
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Table II-2. iH and i3C-NMR data of2 and 3 in CDC13 at 300 K
[6H (LI, Hz)]
2
[6c] [6H J, Hz)]
3
[6c]
1
2
3
4
5
6
7
8
9
10
1la
1lb
12a
12b
13
14
15
16a
16b
17
18
19
20
21
22
23
28a
28b
29a
29b
30
 1'
5.95 (d, 10.1)
6.06 (d, 10.1)
2.82 (d, 11.4)
4.09 (ddd, 12.1, 10.9,
3.1)
4.02 (dd, 3.1, 1.6)
252m
1.63 m
2.56 m
1.59 m
1.92 m
5.57 (dd, 3.6, 1.6)
2.41 (ddd, 15.6, 7.4, 3.6)
2.51 m
2.86 (dd, 10.9, 7A)
O.90 s
1.29 s
7.26 s
6.29 (dd, 1.8, 1.0)
7.39 (dd, 1.8, 1.6)
9.28 s
1.54 s
1.18 s
202.8
128.8
143.9
51.8
44.1
66.3
74.6
44.0
33.2
47.9
 17.9
32.8
47.0
160.4
120.2
34.2
51.8
21.3
16.4
124.3
139.6
11O.9
142.6
15.5
26.1
5.83 (d, 10.1)
6.32 (d, 10.1)
3.35 (d, 11.6)
4.05 (brd, 11.9)
3.99 (d, 2.4)
2.52 m
1.58 m
2.54 m
1.58 m
1.93 m
5.57 (dd, 1.1, 3.4)
2.42 (ddd, 15.4, 7.3, 3.4)
2.52 m
2.86 (dd, 11.1, 7.3)
O.90 s
1.28 s
7.26 brs
6.30m
7.38 (dd, 1.7, 1.7)
1.61 s
1.18 s
3.70 s
203.3
127.0
146.4
47.9
43.3
66.6
75.0
44.2
33.6
48.6
17.9
32.9
47.1
160.7
120.0
34.3
51.9
21.4
16.2
124.4
139.6
111.0
142.6
175.9
17.0
26.4
52.8
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II.2.3 Ceramicine H & I (4 & 5)
B Qo
s
o
R= MLfii,l,.ceramicineH
R=
 o
.llxe
  .rNiNrL.
ceramicine 1
      OH
'-o
   Ceramicine H (4) and ceramicine I (5)
    Ceramicine H {4, [ct]D26 +77 (c O.15, MeOH)} was isolated as a colorless amorphous
solid and had molecular formula of C3iH3s06 as determined by HR-ESI-TOF-MS [m/z
529.2565 (M + Na)', A -O.1 mmu]. wnereas, ceramicine I {5, [or]D26 +13 (c O.3, MeOH)}
possessing molecular formula of C2sH3s06 determined by HR-ESI-TOF-MS [m/z 489.2227
(M + Na)', A -2.6 mmu] was isolated as a colorless amorphous solid. iH and i3C NMR data
(Tables II-3) of4 and 5 were found to be similar to those ofthe previously isolated ceramicine
C i5. Based on the 2D NMR (iH-iH COSY, heteronuclear single quantum coherence (HSQC),
and HMBC) data, 4 was found to be an analogue of ceramicine C but with a tiglate group
attached to C-12 (6c 77.2), whereas 5 was found with acetate group substituted to C-12 (6c
77.2) instead of methacrylate at C-12 of ceramicine C, which was confirmed by HMBC
correlations for H3-5' and H-12 of C-1' (6c 167.7) and the chemical shifts 35'36 of H-3' (6H•
6.58) and C-5' (6c 11.7) in 4 and for H3-2' and H-12 of C-1' (6c 171.0) in 5 (Figure II-6,7).
The side chain attached to C-12 of ceramicine H is suggested to be a tiglate but not of an
angelate based on its i3C chemical shift of C-4' and C-5' (6c 14.3 and 11.7) 37. The relative
structures of 4 and 5 were shown to be similar to that of ceramicine B i5. The NOESY
correlations between H-121H-17 and H3-30 for 4 and 5 indicated that both the tiglate at C-12
and acetate at C-12 were to adopt the P-configurations (Figure II-6 and 7).
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Figure II-7. Selected 2D-NMR correlations for ceramicine I (5)
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Table II-3. iH and i3C-NMR data of4 and 5 in CDC13 at 300 K
[6H (,.J, Hz)]
4
[6c] [6H (LI, Hz)]
S
1
2
3
4
5
6
7
8
9
10
1ia
1lb
12a
12b
13
14
15
16a
16b
17
18
19
20
21
22
23
28a
28b
29a
29b
30
 1'
2'
3'
4'
5'
5.82 (d, 9.6)
6.95 (d, 9.6)
2.69 (d, 12.4)
4.29 (dd, 12.4, 3.2)
4.24 (d, 3.2)
2.59 m
2.27m
2.49 m
5.10 (dd, 9.0, 7.0)
5.68 (dd,
2.45 m
2.55 m
3.04 (dd,
1.08 s
1.16 s
1.2, 3.2)
11.0, 7.8)
7.13 brs
6.22 brs
727 (dd, 1.6, 1.6)
3.63 m
3.79 (d, 6.8)
1.33 s
1.13 s
6.58 (brq, 7.6)
1.72 (brd, 7.6)
1.65 brs
202.4
130.0
151.0
41.8
47.6
73.7
72.0
46.5
36.5
47.2
26.9
77.2
51.7
156.7
122.6
36.4
50.6
16.0
14.2
124.3
140.4
111.8
141.8
79.9
20.1
26.5
167.7
128.6
137.8
14.3
11.7
5.83 (d, 9.6)
6.96 (d, 9.6)
2.69 (d, 12.4)
4.26 (dd, 12.4, 3.2)
4.24 (d, 3.2)
2.60m
2.30 m
2.42 m
5.10 (dd, 9.0, 7.0)
5.68 m
2.47 m
2.53 m
3.04 (dd,
1.04 s
1.16 s
10.8, 8.0)
7.21 brs
6.26 brs
7.33 brs
3.63 m
3.79 (d, 7.2)
1.34 s
1.12 s
1.93 s
l8
[6c]
202.4
130.0
151.1
41.8
47.6
73.7
72.0
46.4
36.2
47.1
26.8
77.2
51.4
156.6
122.6
36.4
50.5
15.9
14.1
124.4
140.2
111.7
142.1
79.9
20.1
26.5
171.0
21.4
IL2.4 CeramicineJ(6)
Go
- .N
   H
     .tttoH!o
Ceramicine J (6)
    Ceramicine J {6, [ct]D25 -88 (c O.5, CHC13)} was isolated as a colorless amorphous solid
and had molecular formula, C26H320s as determined by HR-ESI-TOF-MS [m/z 425.2328
(M+H)', A -O.3 mmu]. IR absorptions suggested the presence of two carbonyls (1724 and
1675 cm-i). iH and i3C NMR data (Tables II-4) revealed 26 carbon resonances due to two
carbonyls, one sp2 quaternary carbons, four sp3 quaternary carbons, five sp2 methines, six sp3
methines, four sp3 methylenes, and four methyls. Among them, two sp2 methines (6c 140.2
and 142.8), two sp3 methines (6c 73.6 and 69.4), and one sp3 methylene (6c 79.8) are
connected to an oxygen atom.
     iH and i3C NMR data (Tables II-4) of 6 were analogous to those ofpreviously reported
ceramicine B i5, but instead an olefin between C-14 and C-15, C-15 (6c 120.3) formed a
carbonyl. Based on data frofri COSY analysis of 6 in CDC13 (Figure II-8), five partial
structures a (from C-2 to C3), b (from C-5 to C-7), c (from C-9 to C-12), d (from C-16 to C-
17), and e (from C-22 to C-23) were deduced. The HMBC correlations for H3-29 ofC-3 to C-
5; H-2 of C-4 and C-10; H3-19 of C-1, C-5, C-9; H3-30 of C-7, C-9, and C-14; and H3-18 of
C-12 to C-14 bridged the partial structure of a, b, and c through C-1, C-8, and C-10, thus
forming a phenantren ring system. The relation between partial structure c and d could be
assigned by HMBC correlations for H3-18 of C-12 to C-14, and C-17; H2-16 and H-14 of C-
15, such that a cyclopentanone was deduced to be attached to the phenantren ring system
through C-13 and C-14. The connectivity ofpartial structure e (B-fury1 ring) to d was shown
by HMBC correlations for H-20 ofC-17, H-21 ofC-20, and C-22. Further analysis ofHMBC
correlations of H3-29 of C-3 and C-5, and H2-28 of C-6, indicated the presence of a
tetrahydrofuran ring at C-4 - C6 and C-28. Therefore, ceramicine J (6) was established as a
new limonoid with a cyclopentanone[ct]phenanthren ring system with a P-furyl ring at C-17,
and a tetrahydrofuran ring.
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Figure II-8. Selected 2D-NMR correlation for ceramicine J (6)
    The relative stereochemistry of 6 was elucidated by ROESY correlations as shown in
computer-generated 3D rendering (Figure II-8). ROESY correlations of H3-29!H-6, and H3-
19 suggested stereochemistry of C-29 methyl group to take as shown in figure II-8. The 3J
proton coupling constants (3.JH-s!H-6 = 12.5 Hz and 3.JH-6!H-7 : O Hz) as well as ROESY
correlations ofH-71H-6 and H-14, and H3-181H-14 indicated that H-6, and H-7 adopted a P-
configurations, and H-5, H-9, and C-18 adopted an ct-configurations as shown in figure II-8.
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Table II-4. iH and i3C-NMR data of6 in CDC13 at 300 K
1
2
3
4
5
6
7
8
9
10
1la
1lb
12a
12b
13
14
15
16a
16b
17
18
19
20
21
22
23
28a
28b
29
30
5.84 (d, 9.7)
6.95 (d, 9.7)
2.61 (d, 12.5)
4.20 (dd, 12.5, 2.9)
4.17 brs
1.73 m
1.71 m
2.54m
1.32 (d, 14.6)
1.94 (dt, 14.6, 2.8)
2.91 s
2.52 (2H, m)
3.49 (t, 9.9)
O.78 s
1.17 s
7.27 s
6.30 s
7.40 s
3.60 (d, 7.1)
3.79 (d, 7.1)
1.32 s
1.07 s
202.5
130.0
151.0
41.8
47.1
73.6
69.4
44.1
43.7
46.4
19.1
34.2
42.1
60.7
219.1
43.4
37.7
27.6
15.0
123.0
140.2
110.8
142.8
79.8
20.0
17.7
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II.2.5 Ceramicine K & L (7 & 8)
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   Ceramicine K (7)
    Ceramicine K {7, [or]D26 +6 (c O.4, CHC13)} was isolated as a colorless amorphous solid
and had molecular formula of C26H3206 as determined by HR-ESI-TOF-MS [m/z 463.2136
(M+Na)', A +3.9 mmu], which was an oxygen larger than ceramicine J (6). IR absorptions
showed the presence of two carbonyls (1747 and 1691 cm-i). iH and i3C NMR data (Tables
II-5) revealed 26 carbon resonance due to two carbonyls, two sp2 quaternary carbons, three
sp3 quaternary carbons, six sp2 methines, six sp3 methines, three sp3 methylenes and four
methyls. In which, two sp2 methines (6c 139.7 and 142.7), and three sp3 methines (6c 65.2,
65.6, and 74.8) are attached to an oxygen atom. Further observation into i3C NMR data, the
presence of an olefin on C-14 and C-15 (6c 160.7 and 120.0, respectively) was observed to
replace the carbonyl on C-15 (6c219.1) as of seen on ceramicine J (6). In addition, HMBC
correlations for H-4 and H3-2' of C-1' included the presence of acetate at C-4 position (6c
65.2). Based on these NMR data including 2D NMR (COSY, HSQC, and HMBC) as well as
HR-RES-TOF-MS, the plane structure of7 was elucidated shown in figure II-9.
2'
o
- 1H-1H COSY
. HMBC y'
Figure II-9. Selected 2D-NMR correlations for ceramicine K (7)
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    The relative stereochemistry of 7 was elucidated by ROESY correlations as shown in
computer-generated 3D drawing (Figure II-9). As shown by Figure II-9, the relative
stereochemistry was shown to be similar to 6. ROESY correlations of H-6!H3-19, and H3-30;
H-7/H-15, and H3-30 suggested the presence of both hydroxyls attached to C-6 and C-7 to
adopt the ot-configuration. In contrast, the 3.J proton coupling constants (3.JH.4iH.s = 4.6 Hz),
along with ROESY correlation ofH-4!H-5 implied the acetate attached to C-4 to adopt the P-
configuration.
                                        C.
                                      - sN
                             o
    H
       OH
  HOH OH
Ceramicine L (8)
    Ceramicine L {8, [or]D27 +14 (c O.3, CHC13)} was isolated as a colorless amorphous with
molecular formula of C2sH3206 as established by HR-ESI-TOF-MS [m/z 435.2147 (M+Na)',
A +2.6 mmu], which was smaller than that of ceramicine K (7) by a CO unit. iH and i3C
NMR data (Tables II-5) of 8 were analogous to those of 7, but instead of acetate attached at
C-4 in 7, the presence of a sp3 quaternary carbon for C-4 with a methyl and a hydroxy group
was suggested by the HMBC correlations H3-29 to C-3, C-4 (6c 71.5), and C-5 (Figure II-1O).
The ROESY correlations between H-6!H3-29 and H3-30, H-7/H3-30, and H3-291H3-19
suggested that all three hydroxyls adopted the ct-configuration (Figure II-1O).
a
 OH OH
- IH-IH COSY
• HMBC
Figure II-1O. Selected 2D-NMR correlations for
    t'
    ge
ceramlclne
tw
ROESY
L (8)
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Table II-5. iH and i3C-NMR data of7 and 8 in CDCI3 at 300 K
[6H (.I, Hz)]
7
[6c] [6H (J, Hz)]
8
[6c]
1
2
3
4
5
6
7
8
9
10
1la
1lb
12a
12b
13
14
15
16a
16b
17
18
19
20
21
22
23
28a
28b
29
30
 P
2'
5.93 (d, 10.0)
6.77 (ddd, 17.1, 10.0,
4.6)
5.65 (t, 4.6)
2.46 (dd, 9.0, 4.6)
4.12 (t, 9.0)
4.05 brs
2.49m
1.62
2.52
1.60
1.93
m
m
m
m
5.58 s
2.43m
2.55 m
2.87 (dd,
O.88 s
1.33 s
7.26 s
6.30 s
7.39 s
1.22 s
2.15 s
11.0, 7.4)
203.7
130.1
139.2
65.2
43 .6
65.0
74.8
47.2
32.7
48.0
17.9
32.7
44.2
160.7
120.0
34.3
52.0
21.3
16.0
124.4
139.7
111.0
142.7
26.3
170.5
21.1
5.75 (d, 10.3)
6.41 (d, 10.3)
2.63 (d, 11.6)
4.39m
3.98 (d, 2.4)
250m
1.55 m
2.55 m
1.59 m
1.92 (dt,
5.58 s
2.42 m
2.54 m
2.87 (dd,
O.89 s
1.25 s
7.26 s
6.30 s
7.39 s
1.62 s
1.19 s
13.0, 2.9)
10.9, 7.3)
203.8
125.6
149.8
71.5
50.9
68.4
75.0
44.3
33.5
49,1
17.8
33.1
47.1
160.6
120.3
34.3
51.9
21.5
15.8
124.4
139.7
111.0
142.7
23.8
26.4
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Chapter III - Absolute Configuration of Ceramicine B
    Absolute stereostructures of a series of ceramicines are still remained to be solved.
Hence, in this report the absolute configuration of ceramicine B, a major limonoid from C.
ceramicus, was elucidated by using the exciton chirality CD method 38. The CD spectrum of
p-Br-benzoyl derivative ofceramicine B was shown in Figure III-IA. At first position, [Xm..
246 nm (Ae -9.89)] was of a negative value, while at the second position [X.,, 225 nm (Ae
14.52)] was of a positive value. This indicates that the chirality of the two chromophores
(benzoate chromophore and ct,B-unsaturated ketone chromophore) was a left-handed screw or
oriented in a counter clockwise manner, as shown in Figure III-IB. Therefore, absolute
configuration at C-7 could be assigned as S.
                                  i:'i,X-.g
                                  SKx,--d..-ne-Lif
    T-
   Egi
   'S wi
                    Wgigfflwt, gem
      Figure III-1. A) CD spectrum. B) 3D structure ofp-Br benzoate ofceramicine B.
    Apart from using exciton chirality method, the crystal structure of ceramicine B was
also determined using X-ray crystallography method. The addition X-ray crystallography
results showed that, total structure of ceramicine B including its absolute structure was
confirmed by the Flack parameter 39, x = -O.O(2) of X-ray analysis for the crystal obtained
from MeOHIH20 (Figure III-2). Therefore, the absolute configuration of ceramicine B was
assigned as (4R, 5S, 6R, 7S, 8R, 9S, 10R, 13S, and 17R).
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Figure III-2. Molecular structure of ceramicine B obtained by X-ray analysis [Flack
                    parameter: x - -O.O(2)].
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  Chapter IV - Anti-Lipid Droplets Accumulation Activity of Ceramicines
IV.1 Introduction
      In our effort to identify compounds as an anti-obesity drug lead, the eight new
limonoids, ceramicines E-L (1-8) isolated from C. ceramicus bark extractwere tested for anti--
LDA activity on mouse pre-adipocyte cell line, MC3T3-G21PA6. Apart from examining their
anti-LDA activity, present study also investigates their structure activity relationship.
IV.2 Results
IV.2.2 Anti-Lipid Droplets Accumulation Activity of Ceramicines
     As a result from anti-LDA screening, we have identified that the methanol extracts ofC.
ceramicus bark to exhibit anti-LDA activity. The extract of C. ceramicus showed a dose
dependent reduction of LDA from 6.25 pglmL to 50 pglmL. Although having weaker anti-
LDA activity compared to berberine, C. ceramicus bark extract exhibited higher cell viability
as showed by mitochondrial succinate dehydrogenase activity (Figure IV-1).
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Figure IV-1. Anti-LDA activity of Chisocheton ceramicus bark methanol extract, hexane
fraction, and ceramicine B on mouse pre-adipocyte cell line, MC3T3-G21PA6 cells were
compared to berberine used a control (bar). Anti-LDA activity was measured using nile red
lipid droplets fiuorescent staining method. Samples cytotoxicity was measured indirectly via
mitochondrial succinate dehydrogenase activity (solid square) using MTT assay. Cells were
pre-incubated 2 days prior to MDI induction. Analysis was carried out on day six. Each data
point represents the mean Å} SD of three independent experiments canied out in triplicate.
      Nile red lipid droplets fluorescent staining result indicated that only hexane fraction
showed promising anti-LDA activity (Figure IV-2) (results not shown for ethyl acetate, n-
butanol and water fraction). Similar to result of prior methanol extract, hexane fraction also
showed anti-LDA activity in a dose dependent manner from 1.56 pglmL to 25 pglmL.
However, decrease in cell viability was observable in the presence of 50 pglmL of hexane
fraction under microscope.
      Further purification carried out on the C. ceramicus bark extract yielded a series of 12
new compounds named as ceramicine A-L. Nile red lipid droplets fluorescent staining result
showed ceramicine B is the most potent compound in inhibiting LDA in MC3T3-G21PA6
cells with estimated ICso at 1.8 pM. Ceramicine B however showed cytotoxicity at
concentration above 25 ptM as microscopic observation showed. While ceramicine A also
showed potent anti-LDA activity, it is weaker compared to ceramicine B with estimated ICso
at 6.2 pM. Both ceramicine A and B showed dose dependent manner in their anti-LDA
activity. On the other hand, ceramicine G and I exhibited a moderate anti-LDA activity with
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slight cytotoxicity on higher concentration. The remaining ceramicines were inactive in
inhibiting LDA activity.
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Figure IV-2. Anti-LDA activity of ceramicines A-L. Treatment conditions and measurement
ofanti-LDA were same as previous mention. A six point serially diluted concentrations (1.56
-
 50 pM) of ceramicine were tested for both anti-LDA activity and cytotoxicity to MC3T3-
G2!PA6 cells. Each data point represents the mean Å} SD of three independent experiments
carried out in triplicate.
IV.2.3 Structure Activity Relationship of Ceramicines
    The preliminary structural activity relationship of 1--8 and the previously isolated
ceramicines A-D were studied. Comparison between most potent ceramicine B with 4 and 5
showed that, substitution of C-12 proton with tiglate or acetate group showed no activity and
reduced activity, respectively to MC3T3-G21PA6 cells. While, substitution with methacrylate
group as in ceramicine C were shown to cause cytotoxicity (Figure IV-3).
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Figure IV-3. Ceramicines B, C, H (4), and I (5) (top). Comparison ofceramicines B
                5 anti-lipid droplets accumulation activity (below).
2 A,.
  ii
1.s 8v
  ibE
1:
  a
  ty
o.s E'
  ge
oh/
, C, 4, and
    By comparing ceramicine B, most potent compound with the inactive compound,
ceramicine D, it is revealed that, the furan ring attached to C-17 were important for elicitation
of anti-LDA activity, as substitution with a furolactone ring completely reduced the anti-LDA
activity (Figure IV-4).
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                  droplets accumulation activity (below).
     On other hand, change from C-14 and C-15 double bond in
carbonyl group in 6 reduced anti-LDA activity. This indicates that
bond is important for anti-LDA activity (Figure IV-5).
ceramicine B
C-14 and C-15
to C-15
 double
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    Additionally, the double bond formed between C-2 and C-3 is important for anti-LDA
activity. As comparison between ceramicine A and E (1), existence of an epoxy group at C-2
and C-3; and substitution of C-4 hydroxyl with an epoxy group showed a complete reversal of
its activity (Figure IV-6).
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    In comparing ceramicine A with 2, and 3 showed that substitution of Ri hydroxyl at C-4
with methyl, and R2 proton with aldehyde or methoxycarbonyl resulted in decrease of anti-
LDA activity (Figure IV-7). The inversion between the C-4 hydroxyl and C-6 acetate of
ceramicine A to C-4 acetate and C-6 hydroxyl of 7 resulted in loss of anti-LDA activity
(Figure IV-7). While comparing ceramicine A and 8, alterations of Ri hydroxyl to methyl and
R2 proton at C-4 with hydroxyl at C-4; and C-6 acetate to hydroxyl also result in loss of anti-
LDA activity (Figure IV-7). However more data are required to confirm the importance of C-
4 and C-6 components on anti-LDA structure activity relationship.
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   Figure IV-7. Ceramicines A, E (1), F (2), G (3), K (7), and L (8) (top). Comparison of
     ceramicines A, 1, 2, 3, 7, and 8 anti-lipid droplets accumulation activity (below).
    On a final note, there is no apparent structure activity relationship correlation between
ceramicine A and B as both structure showed anti-LDA activity. Results showed that,
substitution pattern and stereochemistry at C-4, C-5, C-6, and C-28 are critical to anti-LDA
activity. Thus further studies are thus required to compare ceramicine B which has a
tetrahydrofuran ring form between ring A and B through C-4, C-5, C-6, and C-28 with
ceramicine A that is without the tetrahydrofuran ring.
    Summary on the preliminary structure activity relationship of ceramicines series on
anti-LDA activity against mouse pre-adipocyte cell line, MC3T3--G2!PA6 cells is shown
below (Figure IV-8).
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Chapter V - Mechanism Studies of Ceramicine B on Anti-Lipids Droplets
            Accumulation Activity
V.1 Introduction
    Up to date, most of the events that regulate adipogenesis are well documented.
Adipocytes originate from the same pluripotent mesenchymal stem cells (MSCs) as osteoblast,
chondrocytes, and myocytes but each received distinctive sigrials to differentiate 40. Signals
such as bone morphogenetic proteins (BMPs), transforming growth factor-P (TGF-P), activin,
insulin-like growth factor 1 (IGF-1), interleukin-17 (IL-17), and fibroblast growth factor
(FGF) 1 and 2 have all been reported to initiate the adipogenesis progression 4i47. on other
hand, mixture of 3-isobutyl-1-methylxanthine (IBMX), dexamethasone (DEX), and insulin
(MDI induecer) have been used to stimulate adipocyte differentiation in vitro 48. Upon
induction into adipogenesis, CIEBPP and CIEBP6 are initially expressed are the transcription
factors of the master adipogenic gene, PPARy and CIEBPct 49-50. PPARy and CIEBPct
positively cross regulates each other increasing the expression of adipocyte specific genes
such as glucose transporter type 4 (GLUT4), LPL, and 1 1-beta hydroxysteroid dehydrogenase
(HSDI 1Pl) 5i-53. Apart from CIEBPP and CIEBP6, a well-known key intermediate regulatory
of adipogenesis are krUppel 1ike factors (KLFs). The family members of KLFs include both
the positive and negative regulatory protein is signal transduction for adipocytes
differentiation 54. Up-to-date various regulatory molecules involves in adipogenesis signaling
cascade have so far been reported. All these molecules could be affected by ceramicine in
eliciting anti-LDA activity. Therefore, the focus of this study was elucidation of ceramicine B
properties to inhibit LDA and its mechanism ofaction.
V.2 Results
IV.2.1 Inhibition ofAdipocyte Specific Genes Expression by Ceramicine B
     Ceramicine B was identified to be most potent among ceramicines series (V-IA-D). ln
general, LDA in adipocytes are directly related to adipogenesis. As an initial studies into the
mechanism of anti-LDA activity, mlllYA expression of adipocyte specific genes were
determined. Expression of adipocyte specific genes mRNA was examined at MC3T3-G2fPA6
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cells at pre-differentiation and terminal differentiation state, 7 and 14 days from the start of
MDI induction process, respectively. RNA were harvested from four treatment groups which
were divided into vehicle and MDI with or without ceramicine B. RT-PCR results showed
that, adipocyte specific genes, glucose transporter type 4 (GLUT4) or also known as SLC2A4
and lipoprotein lipase (LPL) were up-regulated during MDI induction but were down-
regulated in the presence of ceramicine B (Figure V-IE). HSDI 1Pl were found up-regulated
from day 7 with or without MDI induction. Down-regulation was also observed in HSDI 1Bl
mRNA expression in the presence ofceramicine B (Figure V-1E).
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Figure V-1. A-D) Picture ofMC3T3-G21PA6 cells taken after 5 days after MDI induction. A)
vehicle control, B) cells treated with ceramicine B at 12.5 pM, C) MDI induced cells D) MDI
induced cells treated with ceramicine B at 12.5 pM. E) RT-PCR data of samples harvested
from MC3T3-G3/PA6 cells at 7 and 14 days. Effect ofceramicine B was tested on adipocytes
specific genes, GLUT4, LPL, and HSDIIPI; and adipogenesis master regulating genes,
PPARy and CIEBPct. Lane 1 - vehicle control at day O, lane 2-5 - samples harvested at day 7
in order the ofvehicle control, cells treated with ceramicine B at 12.5 pM, MDI induced cells,
and MDI induced cells treated with ceramicine B at 12.5 pM. Lane 5-9 - samples harvested at
day 14 with similar order as above. F) Western blot analysis on total cells protein harvested
from MC3T3-G21PA6 cells at day 3 and 6. Changes in protein level of PPARy were
investigated with anti-PPARy monoclonal antibody. Proteins were loaded in the order of
vehicle control, cells treated with 12.5 pM of ceramicine B, MDI induced cells, and MDI
induced cells treated with ceramicine B at 12.5 pM.
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IV.2.2 Inhibition of Adipogenesis Master Regulating Genes, PPARy and C/EBPor
     Expression by Ceramicine B
     MDI induction was shown to up-regulate PPARy and CIEBPa mRNA expressions
(Figure V-IE - lane 4 and -8). However, both the master regulating genes PPARy and
CIEBPct mRNA were not shown to be up-regulated by ceramicine B (Figure V-1E - lane 3, -5,
-
7, and -9). This suggested that down-regulation ofpreviously mentioned GLUT4, LPL and
HSDIIPI mRNA expression might be caused by the down-regulation of these master
regulating genes, PPARy and CIEBPor.
IV.2.3 Inhibition of PPARy Pretein Expression by Ceramieine B
     Western blot analysis was performed on samples taken from an earlier time ofharvest,
day 3 and 6. As result demonstrates, ceramicine B was shown to inhibit the expression
PPARy protein in MC3T3-G21PA6 cells (Figure V-IF). This suggests ceramicine B playing
an inhibitory role in adipocyte differentiation.
IV.2.4 Effect of Ceramicine B on the Expression of Early Regulators of Adipogenesis,
     C/EBPP and C/EBPfi
     ln a typical adipocyte induction pathway, expression of PPARy and CIEBPa were
regulated by CIEBPP and CIEBP6. Since treatment with ceramicine B was recogriized to
down-regulate the master regulators, PPARy and CIEBPct, the early regulators of
adipogenesis, CIEBPP and CIEBP6 were also studied. Both CIEBPB and CIEBP6 mRNA
expression were increased after MDI induction at 2 and 6 hours. Results showed that presence
ofceramicine B did not have significant effect on the expression ofboth CIEBPP and CIEBP6
mRNA (Figure V-2).
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Figure V-2. RT-PCR data ofsamples harvested from MC3T3-G31PA6 cells at thirty minutes,
2 and 6 hours tested on adipogenesis master regulating genes, CIEBPP and C/EBP6; and
KLF2, -3, -4, -6, -7, and -15.
IV.2.5 Effect of Ceramicine B on Krtippel Like Factors (KLFs)
      The ineffectiveness of ceramicine B on C!EBPP and CIEBP6 led to investigation of
KLFs mRNA expression. Therefore, ceramicine B effect on mRNA expression of KLFs, an
important regulator of adipogenesis was assessed. It is identified that KLFs expression did not
commence at 30 minutes after MDI induction. Expression positive KLFs regulator mRNA
(KLF-4, -15) was observed to be up-regulated at 2 and 6 hours after MDI induction. On the
other hand, expression negative KLFs regulator mRNA (KLF-2, -3, -6, and -7) was observed
to be down-regulated at 2 and 6 hours after MDI induction. Studies on expression of KLFs
mRNA showed that ceramicine B have no influence on both the expression of the positive
KLF regulators and negative KLF regulators. Results from RT-PCR on KLFs indicated that
ceramicines mechanism of anti-LDA activity was not via modulation of KLFs mRNA
expression (Figure V-2).
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IV.2.6 Effect of Ceramicine B on the Phosphorylations of Forkhead Box Ol (Foxol)
      Foxol have major implication in adipogenesis by repressing transcription of PPARy
mRNA. Phosphorylation of Foxol led to de-repression of PPARy mRNA transcription.
Phosphorylation of Foxol examined by western blot analysis on total protein samples
harvested from MC3T3-G2/PA6 at 2 hours and 6 hours after MDI induction and treatment
with ceramicine B. The outcome of protein analysis indicated an apparent reduction in the
level of Thr24 phosphorylated Foxol (Figure V-3) although protein level of
unphosphorylated Foxol was initially up-regulated by ceramicine B at 2 hour with or without
MDI induction into adipocyte. However, at hour 6 there is no apparent difference between
Foxol protein expression with or without induction into adipocyte.
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Figure V-3. Western blot analysis on total cells protein harvest from MC3T3-G21PA6 cells at
2 and 6 hours. Phosphorylation of Foxol was investigated with anti-Foxol, and anti-pFoxol
Thr24 monoclonal antibody.
V.3 Discussions
     Ceramicine B was identified to be most potent compound in inhibiting LDA in MC3T3-
G2/PA6 cell lines, followed by ceramicine A while rest of the ceramicines were either weak
or inactive in inhibiting LDA. It was previously reported that ceramicine B is the major
component found in the C ceramicus bark sample with yield up to O.0740/o (wlw) i5. This
could be the main factor in anti-LDA activity of bark methanol and subsequent hexane
fraction.
     In this study, influence of ceramicine B on the expression of GLUT4, LPL, and
HSDI 1Bl mRNA were investigated. GLUT4, an insulin regulated glucose transporter protein
that translocation to plasma membrane facilitates the uptake of glucose into cells 55. This
protein is expressed primarily in muscle and fat tissue, making it an ideal marker for
determining adipocyte differentiation. Apart from GLUT4 another lipid homeostasis related
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gene was also studies, LPL. LPL is an enzyme that hydrolyzes triglycerides such as very low-
density lipoproteins (VLDL), into two free fatty acids and one monoacylglycerol molecule. It
is mostly distributed in adipose, heart, and skeletal muscle tissue 56. HSDIIBI is another
enzyme that is related to the metabolism that it is highly expressed in adipose tissue. This
family of enzyme catalyzes the conversion of inactive cortisone to active cortisol, and vice
versa 57-59. All three GLUT4, LPL, and HSDIIPI mRNA which are mainly expressed in
matured adipocyte were found to be suppressed by ceramicine B. The reduction of these three
genes mR[NA transcripts suggest a preliminary role of ceramicine B in inhibiting the
differentiation of MC3T3-G21PA6 cells into adipocyte.
     Preliminary speculation that ceramicine B might play a role in inhibiting adipogenic
differentiation leads us to fUrther investigate the effect of ceramicine B on the two master
regulating genes of adipogenesis, PPARy and CIEBPct, respectively. Under normal
circumstances, PPARy and CIEBPor were up-regulated during MDI induction and formed
positive-feedback loops that cross-regulates each other promoter. These two master regulating
genes in turn induce a wide range of downstream adipogenic specific genes in developing and
matured adipocytes which include aforementioned GLUT4, LPL and HSDIIBI [30-32].
Decrease in the expression of both PPARy and CIEBPct mRNA further reinforce the
preliminary speculation of ceramicine B playing a role in inhibiting adipocyte differentiation.
To further support this speculation, western blot analysis was performed to determine PPARy
protein level of MC3T3-G21PA6 cells treated with ceramicine B. Data showed down-
regulation of PPARy protein level, thus suggesting ceramicine B play a role in inhibiting
adipocyte differentiation. By suppression of PPARy role in adipocytes differentiation,
ceramicineBalso inhibit LDA activity. .
     Differentiation of MC3T3-G2/PA6 cells into adipocytes begins with MDI induction.
Addition of IBMX or DEX directly influences the up-regulation C/EBPB and CIEBP6 in a
separate manner. Due to the role of CfEBPP and CIEBP6 in regulating PPARy and CIEBPct,
mRNA expression 49'50 of these genes was also examined. However, ceramicine B was found
to be non-qctive to the regulation of these genes. This led to the assumption that ceramicine
B-induced down-regulation of PPARy and CIEBPct mRNA expression was not via regulation
of CIEBPP and CIEBP6,
     Recent studies ascertained that KLFs regulates differentiation adipocytes activity.
Consisting of both positive and negative regulators, KLFs hold an important role in both up-
regulating and down-regulating many key adipogenic markers including PPARy and CIEBPa
5`
. Ineffectiveness of cerarnicine B on CIEBPP and CIEBP6 led us to investigate the
                                     41
regulatory activity of KLFs on PPARy and CIEBPor mRNA expression in MC3T3-G21PA6.
However, ceramicine B was not found to up-regulating or down-regulating KLFs mRNA
expresslon.
     Apart from the effect of IBMX and DEX, adipogenesis is also controlled by insulin
signaling pathway 60. Foxo1, also known as Foxo1A or FKHR, is an important transcriptional
repressor that conveys PPARy transcription, which was released by insulin-induced
phosphoryIation 6i-62. Foxol is regulated by the serineltheorine kinase Akt (PKB), which
phosphorylates Foxo1 at three site, theorine 24, serine 256, and serine 319. Phosphorylation at
these three positions, leads to the nuclear exclusion ofFoxo1 and followed by ubiquination. In
adipocytes, unphosphorylated Foxol binds to the promoter region of PPARy, suppressing its
transcription and preventing adipocyte differentiation 63.
     Treatment with insulin led to phosphorylation of Foxol, and subsequently inactivating
its functions. This causes transcription ofPPARy to be released from repression and proceed
to adipocytes differentiation 64. Western blot analysis indicates that, treatment with ceramicine
B resulted in decrease in Thr24 phosphorylated Foxol protein level but not in
unphosphorylated Foxol (Figure V-3 - lane 7 and -8). This implies that ceramicine B might
play a role in preventing the phosphorylation of Foxol. Thus led to the speculation that
transcription PPARy mRNA was repressed and subsequently causes inhibition of adipocyte
differentiation. Considering that Akt acts on phosphorylation of Foxol as insulin signaling
pathway implies, further studies on ceramicine B effect on Akt signaling is necessary.
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Chapter VI - Conclusion
    Initiative on the search of drug candidates from terrestrial plants as a source of anti-
obesity drug candidates leads to identification of Chisocheton ceramicus from Meliaceae with
promising outcome. Previous studies have yielded four new limonoids, ceramicines A-D from
the C. ceramicus bark extracts. Continuation of C ceramicus bark extracts constituent in
present studies have fhrther yielded eight more new limonoids, ceramicines E-L (Figure VI-1).
In addition, ceramicines were also found to possess anti-LDA activity with ceramicine B
being most potent. The close relationship between LDA and obesity indicates the potential of
ceramicine B as anti-obesity drug candidate.
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    Apart from determining the anti-LDA activity ceramicines, the preliminary structural
activity relationship of ceramicines was also studied. It was observed that the furan ring
attached to C-17, double bond formed between C-2 and C-3, and between C-14 and C15,
important for ceramicines anti-LDA activity. Whereas additional component added to C-12
will result in decrease of anti-LDA activity. Finally, it is understand that, substitution pattern
and stereochemistry of C-4, C-5, C-6, and C-28 appear to be critical for elicitation of anti-
LDA activity. However, further studies are required to determine the importance of the
tetrahydrofuran ring form between ring A and B through C-4, C-5, C-6, and C-28.
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    As this studies suggested, ceramicine B might convey its anti-LDA activity through
interrupting the phosphorylation of Foxol. Thus results in continued repression of PPARy
mRNA expression which inhibition of LDA was due to suppression of adipocyte
differentiation activity. However, additional studies are necessary to fu11y understand the
mechanism of ceramicine B inhibits the phosphorylation of Foxol. Given that Akt acts on
phosphorylation ofFoxol as insulin sigrtaling pathway implies, further studies on ceramicine
B effect on Akt signaling is necessary.
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Experimental Methods
General Experimental Procedures
      iH and 2D NMR spectra were recorded with Bruker AV700 and JEOL ECA600. Each
ceramicine's NMR sample was prepared by dissolving with CDC13 in 2.5 mm microcells
(Kanto Chemicals Co., Inc., Japan) and the residual CHC13 chemical shift used as an internal
standard are 6H 7.26 and 6c 77.0. Standard pulse sequences where used for the 2D NMR
experiments. iH-iH COSY, and NOESY spectra were measured with spectral widths of both
dimensions of 4800Hz, and 8 scans with two dummy scans were accumulated into IK data
points for each of 256 ti increments. NOESY spectra in the phase sensitive mode were
measured with a mixing time of 800 and 30 ms. While for the HSQC spectra in the phase
sensitive mode and HMBC spectra, a total of256 increments of 1K data points were collected.
The (HMBC) spectra with Z-axis PFG, a 50 ms delay time was used for long range C-H
coupling. Zero-filing to IK for Fi and multiplication with squared cosine-bell windows
shifted in both dimensions were performed prior to 2D Fourier transformation.
      Optical rotations were measured on a JASCO DIP-1OOO polarimeter. UV spectra were
recorded on a Shimadzu UVmini-1240 spectrophotometer and IR spectra on a JASCO Fourier
transformlinfrared (FTIIR)-4100 spectrophotometer. CD spectra were recorded on a JASCO
J-820 polarimeter. High-resolution ESI-MS were obtained on a LTQ Orbitrap XL (Thermo
Scientific, USA).
      Merck silica gel 60 (40 - 63 pM) and Nacalai Tesque Cosmosil 140Cis-OPN were
used for chromatography. Separation parameters were examined with Merck silica gel 60 F2s4
or Merck silica gel RP C-18 F2s4 TLC plates. HPLC were perforrned using Cadenza 5CD C18
(10 x 250 mm) and Cosmosil zNAP (10 x 250 mm).
Materials
    The barks of C. ceramicus were collected from Pahang, Malaysia in 1996. The botanical
identification was made by Mr. Teo Leong Eng, Faculty of Science, University of Malaya.
Voucher specimens (Herbarium No. KL4648) are deposited in the Herbarium of Chemistry
Department, University ofMalaya.
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Extraction and Isolation
Smatt Scate Extraction and Isolation
     The dried ground barks of C. ceramicus (500 g) were extracted successively with
methanol and 53 g of extract were obtained. In a small scale experiment, 7 g from the total
extract was successively partitioned with hexane, ethyl acetate, n-butanol, and water. The
hexane-soluble materials were further partitioned with a silica gel column (hexanelEtOAc,
10:O - 1:1, and then CHC131MeOH, 10:O . O:1O). Fraction eluted from the silica gel column
with CHC131MeOH (7:3) was further purified using HPLC with Cadenza 5CD Cis, 10 x 250
mm, under gradient elution (500/o-1000/o MeOH), fiow rate 2.0 mLlmin, UV: 21O nm to yield
ceramicine E (1, 2.0 mg, O.OO040/o yield), and ceramicine F (2, 9.5 mg, O.OO190/o yield), both
as colorless solid. Fraction eluted with CHC131MeOH (1:1) was purified on HPLC with
Cadenza 5CD C18, 10 x 250 mm, under gradient elution (700/o-1000/o MeOH), flow rate 2.0
ml!min, UV: 210 nm to obtain ceramicine G (3, 5.6 mg, O.OOI10/o yield) as colorless solid.
Whereas, fraction eluted with CHC131MeOH (4:6) was purified on HPLC with Cadenza 5CD
C18, 10 x 250 mm, under gradient elution (500/o-1000/o MeOH), flow rate 2.0 mLlmin, UV:
210 nm to afford ceramicine H (4, O.3 mg, O.OOO060/o yield), and ceramicine I (5, 4.3 mg,
O.OO0860/o yield). Previously identified ceramcines B and C were also isolated from hexane
layer i5.
     Ceramicine E (1): Colorless amorphous solid; [a]D28 +20 (c O.5, CHC13); UV (MeOH)
Zmax 203 (e 8640) nm; IR (KBr) v.. 3437, 1718, 1506, 1389, 1372, and 1246 cm-i; iH and '3C
NMR data (Table II-1); ESI-MS m/z 469 (M + H)'; HR-ESI-TOF-MS m/z 469.2206 (M + H;
calcd for C27H3307, 469.2226).
     Ceramicine F (2): Colorless amorphous solid; [ct]D28 +1Ol (c O.5, CHC13); UV (MeOH)
Amax 203 (6 14592) nm; IR (KBr) v.,. 3437, 2980, 2920, 1724, 1679, 1448, and 1388 cm-i; 'H
and '3C NMR data (Table II-2); ESI-MS m/z 447 (M + Na)'; HR-ESI-TOF-MS m/z 447.2120
(M + Na; calcd for C26H320sNa, 447.2147).
     Ceramicine G (3): Colorless amorphous; [or]D28 -39 (c O.5, CHC13); UV (MeOH) 2max
203 (6 11000) nm; IR (neat) v... 3430, 2993, 1717, 1685, and 1260 cm-'; 'H and '3C NMR
data (Table II-2); ESI-MS m/z 477 (M + Na)'; HR-ESI-TOF-MS m/z 477.2244 (M + Na;
calcd for C27H3406Na, 477.2253).
     Ceramicine H (4): Colorless amorphous solid; [or]D26 +77 (c O.15, MeOH); UV
(MeOH) Ama. 203 (e 29900) nm; IR (CC14) v.,. 3418, 2927, 2855, 1703, 1684, 1585, and 1260
46
cm-i ; iH and '3C NMR data (Table II-3); ESI-MS m/z 529 (M + Na)'; HR-ESI-TOF-MS m/z
529.2565 (M + Na; calcd for C3iH3s06Na, 529.2566).
     Ceramicine I (5): Colorless amorphous solid; [ct]D26 +13 (c O.3, MeOH); UV (MeOH)
Zmax 203 (g 14100) nm; IR (CC14) vma. 2933, 1732, 1683, 1246, and 1030 cm-i; iH and '3C
NMR data (Table II-3); ESI-MS m/z 489 (M + Na)'; HR-ESI-TOF-MS m/z 489.2227 (M +
Na; calcd for C2sH3406Na, 489.2253).
Full Scate Extraction and Isolation
     In a fu11 scale experiment, the remaining 46 g extract was also successively panitioned
with hexane, ethyl acetate, n-butanol, and water. The hexane-soluble materials were
preliminary partitioned with a silica gel column (hexanelEtOAc, 1 :O - O:1). Fraction eluted
at hexanelEtOAc, (3:7) was identified as previously identified ceramicine B i5. Fraction
eluted from the silica gel column with hexanelEtOAc (1:9) was further purified a silica gel
column (toluenelEtOAc, 6:1 - 4:1). Fraction eluted from the silica gel column with
toluenelEtOAc (4:1) was finally purified using HPLC with Cosmosil zNAP, 10 x 250 mm,
under isocratic elution {MeOHIH20 (780/o1220/o)}, flow rate 2.0 mL!min, UV: 210 nm to
yield ceramicine J (6, 1.0 mg, O.OO020/o yield as colorless amorphous solid. Fraction eluted
with 1OOO/o EtOAc from the preliminary silica gel column was purified with another silica gel
column with toluenelEtOAc (6:1) under isocratic condition. Eluent No.12 and No.13 was
finally purified using HPLC with Cosmosil zNAP, 10 x 250 mm, under isocratic elution
{MeOHIH20 (780/o!220/o)}, flow rate 2.0 mL/min, UV: 210 nm to yield ceramicine K (7, O.6
mg, O.OOO120/o yield) and ceramicine L (8, O.8 mg, O.OOO160/o yield) together with ceramicines
A and C i4'i5, all isolated as colorless amorphous solid.
     Ceramicine J (6): Colorless amorphous solid; [ct]D25 -88 (c O.5, CHC13); UV (MeOH)
Amax 203 (E 13624) nm; IR (CC13) v.,. 2928, 1724, 1675, 1574 cm-i; iH and i3C NMR data
(Table II-4); ESI-MS m/z 425 (M + H)'; HR-ESI-MS m/z 425.2325 (M + H: calcd for
C26H330s, 425.2328).
     Ceramicine K (7): Colorless amorphous solid; [or]D26 +6 (c O.4, CHC13); UV (MeOH)
Zmax 203 (s 8764.378) nm; IR (CC14) v.,. 2927, 1747, 1691, 1653 cm-i; iH and i3 C NMR
data (Table II-5); ESI-MS m/z 463 (M + Na)'; HR-ESI-MS m/z 463.2136 (M + Na: calcd for
C26H3206, Na, 463.2097).
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     Ceramicine L (8): Colorless amorphous solid; [or]D27 +14 (c O.3, CHC13); UV (MeOH)
2max 203 (6 13241) nm; IR (CC14) v... 2926, 2854, 1689, 1653 cm'i; iH and i3C NMR data
(Table II-5); ESI-MS m/z 435 (M + Na)'; HR-ESI-MS m/z 435.2173 (M + Na: calcd for
C2sH320sNa, 435.2147).
Absolute Configuration
p-Br-benzoate of Ceramicine B
      To a solution of ceramicine B (O.1 mg, 245 ptmol) in CH3Cl (100 pL) was added p-
bromobenzoyl chloride with N,N-dimethyl-4-aminopyridine. The solution was stirred for 4 h
in room temperature. Purification with column chromatography (hexanelethyl acetate, 8:2)
gave a pale yellow solid. CD (MeOH) 2.,. 225 (As +14.52) and 246 (-9.89) nm; iH NMR
(400 MHz, CDC13) 6 O.72 (3H, s), 1.24 (3H, s), 127 (3H, s), 1.34 (3H, s), 1.58 (IH, m), 1.90
(2H, m), 2.26 (2H, m), 2.50 - 2.65 (3H), 2.80 (IH, dd, 9.0, 9.0), 3.32 (IH, d, 7.2), 3.68 (IH, d,
7.2), 4.41 (IH, brd, 11.2), 5.53 (IH, brs), 5.84 (IH, brs), 5.89 (IH, brd, 9.4), 6.22 (IH, brs),
6.94 (IH, d, 9.4), 7.16 (IH, s), 7.33 (IH, brs), 7.53 (2H, d, 8.2), and 7.80 (2H, d, 8.2). ESI-
MS 591 (M + H)'.
X-Ray Crystattography
     Measurement was made on a Rigaku RAXIS RAPID imaging plate area detector with
graphite monochromated Cu-Kct radiation. Crystal data of ceramicine B: A colorless platelet
crystal, orthorhombic, C26H3204, M == 408.54, crystal dimensions O.14 x O.06 x O.02 mm,
space group P2i2i2i (#9), a == 7.30805(17) A, b - 13.4328(3) A, c - 21.6929(15) A, V -
2129.54 A3, Z = 4, D,,i, = 1.274 glcm3. 0f the 25458 reflections that were obtained, 3899
were unique (Rint == O026). The structure was solved by direct methods. Rl = O.0388
(IÅr2.00u(I)). Flack parameter 39 = -O.O(2) (Fridel pairs = 1651). All calculations were
performed using the CrystalStructure crystallographic software package except for refinement,
which was performed using SHELXL-97. The refined fractional atomic coordinates, bond
lengths, bond angles, and thermal parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC). CCDC 802102 contains the supplementary
crystallographic data for this paper. These data can be obtained free of charge via
http:11www.ccdc.cam.ac.ukldeposit, or from the CCDC, l2 Union Road, Cambridge CB2 lEZ,
UK (Fax: +44 1223 336 033; e-mail: deposit@ccdc.cam.ac.uk).
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Anti-Lipid Droplets Accumulation Activity
CeU Culture and Induction into Adipocyte
      MC3T3-G21PA6 murine pre-adipocytes (Riken Cell Bank) were maintained in basal
medium [alpha minimum essential medium (ct-MEM) (WAKO) supplemented with 1OO/o FBS
(Cell Culture Bioscience)]. For the induction of adipocyte differentiation, cells were cultured
for two days followed by addition of MDI inducers (O.5 mM IBMX, 25 nM DEX and
5 pglmL insulin) and samples were added at this time point. Cells were maintained with
inducer and samples for 6-days duration. Basal medium containing inducers and sample were
changed during third day oftreatment for maintenance purpose.
Nite Red Lipid Droptets Ftuorescent Staining
      Anti-LDA activity ofsamples was measured based on the amount ofLDA after 6-days
of incubation with inducers. Berberine chloride (Sigma) was used as a positive control 65. To
quantify LDA, nile red lipid droplets fluorescent staining method with slight modification was
employed 66. Cells were washed twice with PBS, and stained with nile red (1 mglmL) for 1
hour at room temperature. Fluorescence was measured with Promega GloMax@-Multi
Detection System adjusted to measure with excitation wavelength at 525 nm and emission
wavelength from 580-640 nm.
Cytotoxicity
      Samples cytotoxicity was also evaluated indirectly via MTT assay which is based on
mitochondrial succinate dehydrogenase activity and confirmed via microscopic observation.
MC3T3-G21PA6 cells were incubated with samples under the same condition as in assessing
anti-LDA activity. At the end of incubation, 15 pL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma) at 5 mglmL were added to each of the wells.
The cultures were incubated for another 3 h before the cells supernatant are removed. After
the removal of the cells supernatant, 50 pL of dimethyl sulfoxide (DMSO) was added to each
well. The formed formazan crystal was dissolved by re-suspension by pipette. The optical
density was measured using a microplate reader (Bio-Rad, USA) at 550 nm with reference
wavelength at 700 nm.
Reverse Transcriptase-PCR
      Total cellular RNA was prepared from mouse pre-adipocyte cell lines, MC3T3-
G31PA6 from various time ofharvest using TRIzol@ (Ambion). Reverse transcriptions were
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performed using ReverTra Ace kit (TOYOBO). PCR were carried out using with PCR kit
(Qiagen). Synthesized forward and reverse primer sequences are as followed - P-actin
(forward - 5'-TCACCCACACTGTGCCCATCTAC-3', reverse- 5'-
GAGTACTTGCGCTCAGGAGGAGC-3'), PPARy (forward - 5'-
CATGGTTGACACAGAGATGCC-3', reverse - 5'-GGTGGGACTTTCCTGCTAGTA-3'),
C!EBPct (forward - 5'-CACTTGCAGTTCCAGATCGC-3', reverse - 5'-
GTTTGGCTTTATCTCGGCTCT-3'), CIEBPB (forward - 5'-
CACGACTTCCTCTCCGACCTC-3', reverse - 5'-AGCTGCTCCACCTTCTTCTGC-3'),
CIEBP6 (forward - 5'-ACGACGAGAGCGCCATC-3', reverse - 5'-
TCGCCGTCGCCCCAGTC-3'), GLUT4 (forward - 5'-TGGTCAATACGGTCTTCACGT-
3', reverse - 5'-GGACCCATAGCATCCGCAAC-3'), HSDIIBI (forward - 5'-
AATCTCTGGGATAATTAACGC-3', reverse - 5'-GCTTACAGAAGTATCAGGCA-3'),
LPL (forward - 5'-AATCTGGGCTATGAGATCAACA-3', reverse - 5'-
TCTCTCCGGCTTTCACTCG-3'), KLF2 (forward - 5'-GGTCCCCGCAACCCGTTCCC-3',
reverse - 5'-GCCGCATCCTTCCCAGTTGCAAT-3'), KLF3 (forward - 5'-
CCGCCCATTAAGAAGTACTCG-3', reverse - 5'-TGTAGACCTTATTGCACCCAT-3'),
KLF4 (forward - 5'-GCCCTCAAAGTTTGTGCGAAT-3', reverse - 5'-
ATCGCCGGTGCCTTGACAAC-3'), KLF6 (forward - 5'-
GAGGAACTTTCACCCACGAC-3', reverse - 5'-CAAAACGCCACTCACAACC-3'),
KLF7 (forward - 5'-CCATCGCTGTACGTTTAACGG-3', reverse - 5'-
TCTCTTCATATGGAGCGCAAG-3'), KLF15 (forward - 5'-
GGCCAGAAGTTTCCCAAGAACCC-3', reverse - 5'-GTACGGCTTCACACCCGAGT-3').
All PCR products were separated by 1.50/o agarose gel electrophoresis and visualized by
ethidium bromide staining.
PVestern Btotting
    Total cellular protein was prepared from MC3T3-G31PA6 cells from various time of
harvest. Total protein concentrations were quantified using BCA protein assay kit (Pierce).
Twenty micrograms of total protein extract were loaded into each well of a SDS-
polyacrylamide gel. Separated proteins were transferred to PVDF membrane (Amersham
HybondTM - P, GE Healthcare). Primary antibody was prepared by diluting in BlockAceGD.
Primary antibodies used in this study are PPARy (Santa Cruz Biotechnology), phospho-
FoxOl (Thr24)IFox03a (Thr32) (Cell Signaling Technology), and FoxOl (C29H4) (Cell
Signaling Techonology). Horseradish peroxidase-linked secondary antibody was used in this
50
study (Amersham, GE Healthcare). Fluorescence was detected using
(WAKO) and viewed with UV Transilluminator Imaging System.
immunostar@ LD kit
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Appendix 4. HSQC spectrum of 1 in CDC13
58
Ll.ul,L iLV.-U
.
.
.
i-
.
.
.
"
7 .--.
.
-.
-
-
1.
,,
.
.
.
--
--
.
"
'
.
11 109 1 O-1
ppm
 o
2a
40
6e
80
1OO
120
140
ppm
Appendix 5. HMBC spectrum of 1 in CDC13
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61
1"-"u"--Nde
t.+-.-.....-- t-t-v.r"--- -tt '
, .
-e "tie,-
.
-
.
.
!-
t-.-,.-
,.
.
-e.
.
'.
1:! tt"
,
;1
'
-
-t
-.-
",
'
1
--
--
.
--
.
--
`
--
,
-e- ,
11 10 9 8
Appendix 11 . HMBC spectrum of2 in CDC13
-
1
ppm
 o
20
40
60
80
1OO
120
140
ppm
j
-
.,llll
  =]i
   "=t
     l
     '
   -il
.-
----
E,
     i
     1
L
r-+-LaL
"-
nidiJ.",
" t
Tp---
` i't
tl
lt
,b!S'.-1
.t
.-..
rt..t e
-
c
,te
-e
,
"
-
S"ny''
b
4• t"J7'
-. -
'
g
o'
L /;- ' ;'t'''' 4T:p
t-t
. ttt't
tlii
.
.,
]dl--
"4r-'t-'
i'iIe 't",
,,
,t- ,
-t
,a
t
'
s'
.Y
fid,
s;g.
--
lttt•l
'
'
t"'
`
eg",t
.v
tt."-
-
,
`.,
'
.
:
cJdi''
•-
: or
si
L-
•i,
tl
'
.
..
t
:
-
r
. a,,
t:
`
i c o i+,,';
ss"
'
8.0 7.5 7.0 6.S 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1,O O.5 O.O
    Appendix 12. NOESY spectrum of2 in CDC13
ppm
o
1
2
3
4
5
6
7
8
ppm
62
7.s 7.e 6.S G.e 5.5 5.e 4.5 4.e 3.5 3.0 2.S 2.G l.S t.O OS pprn
Appendix 13. 'H NMR spectrum of3 in CDC13
l
T
t ll /
e
2ee 190 180 17e l6e 1ffa i4e 13o leg "e loa gcr so 7o 6e se 4o 3e 2e
Appendix 14. i3C NMR spectrum of3 in CDC13
ppm
63
    l
    3
    tt•
    =
     1
     ]
    .g
   --ct
     l
   g
:b
e
,
, e .
'
'
--
'
" '
}" i , .
'
,
::
tl
fi,,
,
12 11 10 9
 Appendix ls. i H-iH COSY spectrum of3 in CDC13
m' ua '-' ' J - -' "---hL-- .xkrLMJza
  po! m
   j•
ii
  Il
O ppm
. vt
.-
"-
.
.
.
.
.
e
.
.
'
.
   Appendix 16. HSQC spectrum of3 in CDC13
   --- ppm
      o
      20
      40
      60
      80
      1OO
      120
      140
O -1 PPM
64
    1
    1
    l
   -(•
   ,
   1
    1
    1
   ;
   :,
   =i,
    1
    l
    l
U-- 1 1.
.L .-,,wd.LiLL
. . :
-t'-
-
.
.
.
-
--.
.,}-
t
-
.
.
--
.
.
--
.
. ::
-•-,c--
-
'
.
.
.
-
-
--
i
.
--
.
. --
. .
.
11
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Appendix 49. X-ray crystallography atomic coordinates ofceramicine B
Atoms x y z Atoms x y z
 Ol
 02
 03
 04
 Cl
 C2
 C3
 C4
• C5
 C6
 C7
 C8
 C9
 CIO
 CI1
 C12
 C13
 C14
 C15
 C16
 C17
 C18
 C19
 C20
 C21
 C22
 C23
 C28
 C29
 C30
 H30
O.51452(19)
-
O.1565(2)
O.0341(2)
O.5948(2)
O.3737(2)
O.3771(3)
O.2359(3)
O.0511(2)
O.0821(2)
-
O.0994(2)
-
O.0746(2)
O.0215(2)
O.2069(2)
O.1892(2)
O.3132(3)
O.3392(3)
O.2521(2)
O.0641(2)
-
O.0539(3)
O.0306(3)
O.2024(2)
O.3761(3)
O.1112(3)
O.3544(2)
O.4665(3)
O.4166(3)
O.5592(3)
-
O.0467(3)
-
O.0736(3)
-
O.1145(3)
O.OO43
O.73127(12)
O.75555(10)
O.57547(10)
O.10047(11)
O.76258(15)
O.86072(15)
O.90401(16)
O.85617(15)
O.74557(13)
O.69982(14)
O.58967(15)
O.53942(14)
O.59305(14)
O.70806(15)
O.53533(16)
O.42668(17)
O.38539(14)
O.43081(14)
O.36243(16)
O.26024(17)
O.27308(14)
O.40169(18)
O.73734(16)
O.20067(13)
O.16224(16)
O.15936(15)
O.10071(16)
O.84578(15)
O.91075(16)
O.53819(17)
O.6174
O.68024(7)
O.53827(6)
O.52530(6)
O.64126(7)
O.65694(9)
O.62491(10)
O.59681(1 1)
O.59583(9)
O.60674(8)
O.59222(9)
O.57879(9)
O.63457(9)
O.65063(8)
O.66210(8)
O.70003(9)
O.68797(12)
O.62912(9)
O.61966(8)
O.60087(11)
O.59632(11)
O.63586(9)
O.57323(12)
O.72623(8)
O.62410(8)
O.66668(10)
O.56683(9)
O.58000(10)
O.53344(1O)
O.64162(10)
O.68916(10)
O.4984
H2
H3
H5
H6
H7
H9
HlIA
HIIB
H12A
H12B
H15
H16A
H16B
H17
Hl8A
H18B
H18C
H19A
H19B
H19C
H21
H22
H23
H28A
H28B
H29A
H29B
H29C
H30A
H30B
H30C
O.4902
O.2529
O.16
-
O.1872
-
O.1973
O.2828
O.4353
O.2484
O.2889
O.4722
-
O.1782
O.0618
-
O.0515
O.1636
O.4919
O.4003
O.3156
-
O.0228
O.1511
O.1561
O.4581
O.3662
O.6268
-
O.1255
O.0434
-
O.1906
-
O.0954
-
O.O146
-
O.0552
-
O.2223
-
O.1521
O.8956
O.9664
O.7253
O.71
O.5583
O.587
O.5664
O.543
O.3893
O.413
O.3762
O.2432
O.2085
O.2631
O.3663
O.473
O.3762
O.735
O.8049
O.6906
O.1762
O.1714
O.064
O.9043
O.8398
O.8754
O.9788
O.9129
O.5086
O.4987
O.6065
O.6245
O.577
O.571
O.627
O.5724
O.6125
O.7047
O.7398
O.7235
O.6864
O.5913
O.5532
O.6134
O.6796
O.5794
O.5683
O.5361
O.725
O.7367
O.7574
O.7095
O.5272
O.5503
O.5255
O.4995
O.6449
O.6271
O.6822
O.7253
O.678
O.6988
81
